Advances in the biology and therapy of chronic myeloid leukemia: proceedings from the 6th Post-ASH International Chronic Myeloid Leukemia and Myeloproliferative Neoplasms Workshop.
Leuk. Lymphoma., Dec (2012)
Initial molecular response at 3 months may predict both response and event-free survival at 24 months in imatinib-resistant or -intolerant patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase treated with nilotinib.
J. Clin. Oncol., Dec;30(35):4323-9 (2012)
A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia.
Blood., Nov;120(19):3898-905 (2012)
Pretransplant MRD: the light is yellow, not red.
Blood., Jul;120(2):244-6 (2012)
Five-group cytogenetic risk classification, monosomal karyotype, and outcome after hematopoietic cell transplantation for MDS or acute leukemia evolving from MDS.
Blood., Aug;120(7):1398-408 (2012)
Mutations in the DNMT3A exon 23 independently predict poor outcome in older patients with acute myeloid leukemia: a SWOG report.
Leukemia., Jun (2012)
The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation.
Blood., Mar;119(11):2657-64 (2012)
Chronic myelogenous leukemia.
J Natl Compr Canc Netw., Jan;10(1):64-110 (2012)
IL-6 controls leukemic multipotent progenitor cell fate and contributes to chronic myelogenous leukemia development.
Cancer Cell., Nov;20(5):661-73 (2011)
The biology of chronic myelogenous leukemia progression: who, what, where, and why?
Hematol. Oncol. Clin. North Am., Oct;25(5):967-80, v (2011)
BCR-ABL transcript dynamics support the hypothesis that leukemic stem cells are reduced during imatinib treatment.
Clin. Cancer Res., Nov;17(21):6812-21 (2011)
Prognostic implications of the IDH1 synonymous SNP rs11554137 in pediatric and adult AML: a report from the Children's Oncology Group and SWOG.
Blood., Oct;118(17):4561-6 (2011)
Chronic myeloid leukemia 2011: successes, challenges, and strategies--proceedings of the 5th annual BCR-ABL1 positive and BCR-ABL1 negative myeloproliferative neoplasms workshop.
Am. J. Hematol., Sep;86(9):811-9 (2011)
SHP-1 expression accounts for resistance to imatinib treatment in Philadelphia chromosome-positive cells derived from patients with chronic myeloid leukemia.
Blood., Sep;118(13):3634-44 (2011)
Measuring response to BCR-ABL inhibitors in chronic myeloid leukemia.
Cancer., Jan;118(2):300-11 (2012)
NCCN Task Force report: tyrosine kinase inhibitor therapy selection in the management of patients with chronic myelogenous leukemia.
J Natl Compr Canc Netw., Feb;9 Suppl 2:S1-25 (2011)
Chronic myeloid leukemia 2010: where are we now and where can we go?
Hematology Am Soc Hematol Educ Program., 2010:122-8 (2010)
Southwest Oncology Group Study S0530: a phase 2 trial of clofarabine and cytarabine for relapsed or refractory acute lymphocytic leukaemia.
Br. J. Haematol., Dec;151(5):430-4 (2010)
Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results.
Blood., Jan;117(4):1141-5 (2011)
Comprehensive evaluation of time-to-response parameter as a predictor of treatment failure following imatinib therapy in chronic phase chronic myeloid leukemia: which parameter at which time-point does matter?
Am. J. Hematol., Nov;85(11):856-62 (2010)
Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS).
Blood., Nov;116(19):3758-65 (2010)
Regulation of myeloid leukaemia by the cell-fate determinant Musashi.
Nature., Aug;466(7307):765-8 (2010)
Molecular alterations of the IDH1 gene in AML: a Children's Oncology Group and Southwest Oncology Group study.
Leukemia., May;24(5):909-13 (2010)
Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML.
Blood., Mar;115(12):2372-9 (2010)
Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and
J. Clin. Oncol., Jan;28(3):424-30 (2010)
Molecular monitoring of patients with chronic myeloid leukemia: clinical examples from a non-trial setting.
Clin Lymphoma Myeloma., 9 Suppl 4:S391-4 (2009)
NCCN clinical practice guidelines in oncology: chronic myelogenous leukemia.
J Natl Compr Canc Netw., Oct;7(9):984-1023 (2009)
NCCN task force report: molecular markers in leukemias and lymphomas.
J Natl Compr Canc Netw., Jul;7 Suppl 4:S1-34, quiz S35-6 (2009)
Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations.
Blood., Dec;114(24):4944-53 (2009)
How I monitor residual disease in chronic myeloid leukemia.
Blood., Oct;114(16):3376-81 (2009)
The derivation of diagnostic markers of chronic myeloid leukemia progression from microarray data.
Blood., Oct;114(15):3292-8 (2009)
The preferentially expressed antigen in melanoma (PRAME) inhibits myeloid differentiation in normal hematopoietic and leukemic progenitor cells.
Blood., Oct;114(15):3299-308 (2009)
Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up.
Blood., Jun;113(25):6322-9 (2009)
Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group.
Blood., Jun;113(26):6558-66 (2009)
Optimizing timing of secondary tyrosine kinase therapy in chronic myeloid leukemia.
Clin Lymphoma Myeloma., Mar;8 Suppl 3:S89-94 (2008)
Monitoring treatment results in patients with chronic myelogenous leukemia.
Clin Adv Hematol Oncol., Aug;6(8):577-8, 586 (2008)
Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials.
Blood., Oct;112(8):3330-8 (2008)
MicroRNA discovery and profiling in human embryonic stem cells by deep sequencing of small RNA libraries.
Stem Cells., Oct;26(10):2496-505 (2008)
Molecular classification of acute myeloid leukemia: are we there yet?
J. Clin. Oncol., Oct;26(28):4539-41 (2008)
Structural and numerical variation of FLT3/ITD in pediatric AML.
Blood., May;111(10):4930-3 (2008)
DDX3Y encodes a class I MHC-restricted H-Y antigen that is expressed in leukemic stem cells.
Blood., May;111(9):4817-26 (2008)
Tumour necrosis factor-induced gene expression in human marrow stroma: clues to the pathophysiology of MDS?
Br. J. Haematol., Feb;140(4):444-53 (2008)
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia.
Blood., Feb;111(4):1834-9 (2008)
The Biology of CML blast crisis.
Hematology Am Soc Hematol Educ Program., 384-91 (2007)
Identification of genes with abnormal expression changes in acute myeloid leukemia.
Genes Chromosomes Cancer., Jan;47(1):8-20 (2008)
Development of an integrated assay for detection of BCR-ABL RNA.
Clin. Chem., Sep;53(9):1593-600 (2007)
Monitoring chronic myelogenous leukemia in the age of tyrosine kinase inhibitors.
J Natl Compr Canc Netw., May;5(5):497-504 (2007)
Chronic myelogenous leukemia.
J Natl Compr Canc Netw., May;5(5):474-96 (2007)
Monitoring patients with chronic myeloid leukemia receiving Abl tyrosine kinase inhibitor therapy.
Clin Lymphoma Myeloma., Mar;7 Suppl 2:S58-63 (2007)
Connective tissue growth factor (CTGF) expression and outcome in adult patients with acute lymphoblastic leukemia.
Blood., Apr;109(7):3080-3 (2007)
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.
N. Engl. J. Med., Dec;355(23):2408-17 (2006)
Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia.
Blood., Apr;109(7):2791-3 (2007)
The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemia.
Blood., Feb;109(4):1782-9 (2007)
Use of gene expression microarrays for the study of acute leukemia.
Expert Rev. Mol. Diagn., Sep;6(5):733-47 (2006)
Monitoring BCR-ABL in the treatment of chronic myeloid leukemia by polymerase chain reaction.
Curr Hematol Malig Rep., Sep;1(3):152-9 (2006)
Clinical implications of FLT3 mutations in pediatric AML.
Blood., Dec;108(12):3654-61 (2006)
FLT3 internal tandem duplication in CD34+/CD33- precursors predicts poor outcome in acute myeloid leukemia.
Blood., Oct;108(8):2764-9 (2006)
Role of allogeneic stem cell transplantation in FLT3/ITD-positive AML.
Blood., Jul;108(1):400; author reply 400-1 (2006)
Reduced incidence of acute and chronic graft-versus-host disease with the addition of thymoglobulin to a targeted busulfan/cyclophosphamide regimen.
Biol. Blood Marrow Transplant., May;12(5):573-84 (2006)
Evidence of donor-derived hematologic malignancies after hematopoietic stem cell transplantation.
Biol. Blood Marrow Transplant., May;12(5):511-7 (2006)
Gene expression profiling of adult acute myeloid leukemia identifies novel biologic clusters for risk classification and outcome prediction.
Blood., Jul;108(2):685-96 (2006)
Gene expression changes associated with progression and response in chronic myeloid leukemia.
Proc. Natl. Acad. Sci. U.S.A., Feb;103(8):2794-9 (2006)
Size of FLT3 internal tandem duplication has prognostic significance in patients with acute myeloid leukemia.
Blood., May;107(9):3724-6 (2006)
Chronic myelogenous leukemia.
J Natl Compr Canc Netw., Nov;3(6):732-55 (2005)
HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with chronic myeloid leukemia.
Biol. Blood Marrow Transplant., Apr;11(4):272-9 (2005)
Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia.
J. Clin. Oncol., Jun;23(16):3819-29 (2005)
Randomized trial of allogeneic related bone marrow transplantation versus peripheral blood stem cell transplantation for chronic myeloid leukemia.
Biol. Blood Marrow Transplant., Feb;11(2):85-92 (2005)
Methylenetetrahydrofolate reductase genotype affects risk of relapse after hematopoietic cell transplantation for chronic myelogenous leukemia.
Clin. Cancer Res., Nov;10(22):7592-8 (2004)
Fanconi anemia type C-deficient hematopoietic cells are resistant to TRAIL (TNF-related apoptosis-inducing ligand)-induced cleavage of pro-caspase-8.
Exp. Hematol., Sep;32(9):815-21 (2004)
Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia.
Hematol. Oncol. Clin. North Am., Jun;18(3):685-702, x (2004)
Gene expression profiles at diagnosis in de novo childhood AML patients identify FLT3 mutations with good clinical outcomes.
Blood., Nov;104(9):2646-54 (2004)
Kinetics of engraftment in patients with hematologic malignancies given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning.
Blood., Oct;104(8):2254-62 (2004)
Elevated expression of the AF1q gene, an MLL fusion partner, is an independent adverse prognostic factor in pediatric acute myeloid leukemia.
Blood., Nov;104(10):3058-63 (2004)
Individual-specific variation of gene expression in peripheral blood leukocytes.
Genomics., Jun;83(6):980-8 (2004)
Signatures of environmental exposures using peripheral leukocyte gene expression: tobacco smoke.
Cancer Epidemiol. Biomarkers Prev., Mar;13(3):445-53 (2004)
Novel FLT3 point mutations within exon 14 found in patients with acute myeloid leukaemia.
Br. J. Haematol., Feb;124(4):481-4 (2004)
Single-stranded linear amplification protocol results in reproducible and reliable microarray data from nanogram amounts of starting RNA.
Genomics., Feb;83(2):321-31 (2004)
Survival after second hematopoietic stem cell transplantation for recurrent pediatric acute myeloid leukemia.
Biol. Blood Marrow Transplant., Nov;9(11):706-13 (2003)
Progenitor cell involvement is predictive of response to induction chemotherapy in paediatric acute myeloid leukaemia.
Br. J. Haematol., Nov;123(3):431-5 (2003)
Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia.
N. Engl. J. Med., Oct;349(15):1423-32 (2003)
Tumor suppressor gene alteration in adult acute lymphoblastic leukemia (ALL). Analysis of retinoblastoma (Rb) and p53 gene expression in lymphoblasts of patients with de novo, relapsed, or refractory ALL treated in Southwest Oncology Group studies.
Leukemia., Dec;10(12):1901-10 (1996)
Expression of myeloid antigens by blast cells in acute lymphoblastic leukemia of adults. The Southwest Oncology Group experience.
Leukemia., Dec;8(12):2118-26 (1994)